2006 proposed fee schedule - American Society of Clinical Oncology

Drugs
TABLE 23
Percent by which ASP+6
percent rates are below 95
percent of AWP prices
(except EPO)
(percent)
Epogen 7.5*
Calcitriol 38.7
Doxercalciferol 10.6
Iron_dextran 37.8
Iron_sucrose 45.1
Levocarnitine 69.7
Paricalcitol 26.0
Sodium_ferric_glut 42.6
Alteplase, Recombinant 22.5
Vancomycin 42.6
*Compared to the $10.00 statutory price.
We estimate that these ten drugs represent nearly 92
percent of total CY 2005 drug payments to independent
134
facilities. To account for the drug spread related to the 8
percent of drug expenditures for which we do not have
pricing data, we applied the weighted average to 100 percent
of aggregate drug spending projections for independent
facilities, producing a projected difference of
$343 million. The weighted average is applied to 100
percent of drug spending projections for independent
facilities to account for the drug spread related to the 8
percent of drugs expenditures for which we do not have
pricing data.
We combined the CY 2005 figures of $18 million for the
hospital-based facilities and $343 million for the
independent facilities, for a total of $362 million. We